ELTX ELTX
Company Profile ↓Company Overview
ELTX (ELTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -91.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.62% |
| 1 Year: | -91.87% |
Stock Price Performance
| 1 Year: | -67.88% |
| 6 Months: | -60.67% |
| 3 Months: | -69.88% |
| 1 Month: | +13.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -10.6% CAGR over 5 years.
- Trading 78.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 865.00K | 729.00K | 827.00K | 371.00K | 540.00K | 1.46M | 1.65M | 653.00K | 0 | 0 | - | - | - | - | - | - | - | - | - |
| Operating Income | -12.57M | -17.27M | -11.59M | -19.94M | -18.24M | -15.76M | -14.48M | -6.23M | -5.77M | -7.80M | -7.78M | -10.77M | -10.24M | -10.92M | -10.34M | -10.74M | -10.09M | -8.04M | -10.60M |
| Net Income | -13.22M | -20.34M | -17.67M | -36.69M | -17.07M | -15.70M | -7.06M | -7.30M | -7.20M | -8.03M | -7.56M | -10.66M | -11.83M | -7.23M | -18.84M | -11.21M | -10.56M | -10.08M | -11.82M |
| Diluted EPS | -0.91 | -1.40 | -1.19 | -1.56 | -0.58 | -0.53 | -0.48 | -23.20 | -22.67 | -24.77 | -2.61 | -1.27 | -1.15 | -0.64 | -1.39 | -0.87 | -0.66 | -0.60 | -0.65 |
| R&D Expense | 9.60M | 12.23M | 6.09M | 14.30M | 14.44M | 13.29M | 11.67M | 5.04M | 4.59M | 5.48M | 4.94M | 7.26M | 7.56M | 8.18M | 7.21M | 7.78M | 7.01M | 5.04M | 6.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.88M | 28.31M | 2.30M | - | - | - |
| Operating Income | -55.27M | -39.31M | -23.73M | -35.74M | -44.99M | -37.71M |
| Net Income | -80.11M | -54.57M | -28.21M | -35.20M | -51.90M | -39.57M |
| Diluted EPS | -5.43 | -1.93 | -89.27 | -6.96 | -4.25 | -2.58 |
| R&D Expense | 38.98M | 48.70M | 18.10M | 23.85M | 33.66M | 24.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.35M | 96.51M | 22.66M | 27.15M | 28.18M | 25.86M |
| Total Equity | -18.59M | -90.45M | -74.54M | -102.14M | 11.37M | -11.31M | 1.64M |
| Cash & Equivalents | - | 34.61M | 88.76M | 6.16M | 12.89M | 17.62M | 18.56M |
| Long Term Debt | - | 635.00K | 0 | - | - | 20.03M | 9.41M |
| Total Liabilities | - | 137.80M | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Current Liabilities | - | 107.45M | 11.30M | 6.87M | 9.76M | 11.52M | 8.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.89M | - | -22.18M | -32.69M | -37.07M | -36.95M |
| Investing Cash Flow | -41.00K | - | -654.00K | -32.00K | -84.00K | -16.00K |
| Financing Cash Flow | 52.41M | - | 21.20M | 38.61M | 42.32M | 36.70M |
| Capital Expenditure | -41.00K | - | -654.00K | -66.00K | -87.00K | -16.00K |
| Free Cash Flow | -22.93M | - | -22.83M | -32.76M | -37.16M | -36.97M |
| Net Change in Cash | - | - | -1.63M | 5.89M | 5.17M | -273.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -1,919.2% | -138.8% | -1,031.4% | - | - | - |
| Net Margin % | -2,781.5% | -192.8% | -1,225.9% | - | - | - |
| ROE % | 88.6% | 73.2% | 27.6% | -309.5% | 458.8% | -2,418.8% |
| ROCE % | 92.0% | -46.1% | -150.2% | -205.5% | -270.1% | -212.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELTX
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the c…
Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
US stocks look set to open higher in Thursday's trading session as investors parse key employment da
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
Elicio Therapeutics expects to generate net proceeds of about $15 million from the stock offering.
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that …
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that …
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapyComplete responses (“CRs”) are…
ELTX — Frequently Asked Questions
What is the current share price of ELTX?
As of 2026-08-05 17:25 PDT, ELTX trades at $3.19 on NASDAQ/NYSE. Its 52-week range is $2.76 to $14.85.
What is the P/E ratio of ELTX?
ELTX trades at a trailing price-to-earnings (P/E) ratio of -1.24.
Is ELTX a good stock to buy?
This page provides a data-driven analysis of ELTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.